Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7720432 | 0.83 | GPR119 (0.52) | GPR119POLBUSP30NAMPTGRM5 | |
| SCHEMBL21640139 | 0.79 | USP30 (0.60) | GPR119POLBUSP30 | |
| SCHEMBL2992043 | 0.79 | GPR119 (0.53) | GPR119POLBNR1H2NAMPTGRM5 | |
| SCHEMBL30989308 | 0.78 | GPR119 (0.41) | GPR119POLBUSP30NR1H2HPGD | |
| SCHEMBL25205310 | 0.78 | GPR119 (0.41) | GPR119POLBUSP30NR1H2HPGD | |
| SCHEMBL2370711 | 0.78 | GPR119 (0.47) | GPR119POLBUSP30GRM5MAPT | |
| SCHEMBL2882463 | 0.78 | KDM4E (0.51) | GPR119USP30NAMPTRORC | |
| SCHEMBL18228070 | 0.77 | GPR119 (0.53) | GPR119POLBNAMPTGRM5MAPT | |
| SCHEMBL2995903 | 0.77 | GPR119 (0.51) | GPR119POLBUSP30NR1H2NAMPT | |
| SCHEMBL4911832 | 0.76 | LMNA (0.51) | GPR119POLBUSP30NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210276977-A1 | BICYCLIC INHIBITORS OF HISTONE DEACETYLASE | ALKERMES, INC. | 2021-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210276977-A1 | BICYCLIC INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC2, HDAC11 | GPR119 1656/4885POLB 684/4885USP30 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.